{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:46:42Z","timestamp":1791298002682,"version":"4.1.0"},"reference-count":49,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:00:00Z","timestamp":1502755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1210\/en.2017-00592","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T18:09:16Z","timestamp":1502820556000},"page":"3097-3108","source":"Crossref","is-referenced-by-count":12,"title":["Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice"],"prefix":"10.1210","volume":"158","author":[{"given":"Petra","family":"Bullova","sequence":"first","affiliation":[{"name":"Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"},{"name":"Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Cougnoux","sequence":"additional","affiliation":[{"name":"Section on Molecular Dysmorphology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Marzouca","sequence":"additional","affiliation":[{"name":"Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Kopacek","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"issue":"5","key":"2019041121342033200_B1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr Med Chem"},{"issue":"10","key":"2019041121342033200_B2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019041121342033200_B3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.17.6.879","article-title":"The potential of proteasome inhibitors in cancer therapy","volume":"17","author":"Sterz","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2019041121342033200_B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem Biol"},{"issue":"18","key":"2019041121342033200_B5","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.2174\/13816128113199990338","article-title":"Dissecting bortezomib: development, application, adverse effects and future direction","volume":"19","author":"Cao","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2019041121342033200_B6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cellsig.2012.10.004","article-title":"Bortezomib\/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells [published correction appears in Cell Signal. 2015;27(3):727 and 27(5):1019-1020]","volume":"25","author":"Selimovic","year":"2013","journal-title":"Cell Signal"},{"issue":"10","key":"2019041121342033200_B7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol"},{"issue":"5","key":"2019041121342033200_B8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"issue":"6","key":"2019041121342033200_B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"2019041121342033200_B10","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","article-title":"Discovery and development of the anticancer agent salinosporamide A (NPI-0052)","volume":"17","author":"Fenical","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"2019041121342033200_B11","unstructured":"NCT00396864\n          \n          . Phase 1 clinical trial of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00396864?term=NPI-0052&rank=4. Accessed 11 October 2016."},{"key":"2019041121342033200_B12","unstructured":"NCT02330562\n          . Stage 1: marizomib + bevacizumab in WHO Gr IV GBM; stage 2: marizomib alone. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02330562?term=NPI-0052&rank=6. Accessed 11 October 2016."},{"issue":"2","key":"2019041121342033200_B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/cphy.c130034","article-title":"Pathophysiology and diagnosis of disorders of the adrenal medulla: focus on pheochromocytoma","volume":"4","author":"Lenders","year":"2014","journal-title":"Compr Physiol"},{"key":"2019041121342033200_B14","first-page":"e90458","volume-title":"PLoS One","author":"Giubellino","year":"2014"},{"issue":"11","key":"2019041121342033200_B15","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1210\/en.2015-1476","article-title":"Inhibitory effect of the noncamptothecin topoisomerase I inhibitor LMP-400 on female mice models and human pheochromocytoma cells","volume":"156","author":"Schovanek","year":"2015","journal-title":"Endocrinology"},{"issue":"2","key":"2019041121342033200_B16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/en.2012-1854","article-title":"Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice","volume":"154","author":"Giubellino","year":"2013","journal-title":"Endocrinology"},{"issue":"2","key":"2019041121342033200_B17","doi-asserted-by":"crossref","first-page":"e56083","DOI":"10.1371\/journal.pone.0056083","article-title":"Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma","volume":"8","author":"Giubellino","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019041121342033200_B18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-0032-1331211","article-title":"Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors","volume":"45","author":"Matro","year":"2013","journal-title":"Horm Metab Res"},{"issue":"1","key":"2019041121342033200_B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12022-012-9194-y","article-title":"Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?","volume":"23","author":"Korpershoek","year":"2012","journal-title":"Endocr Pathol"},{"issue":"7","key":"2019041121342033200_B20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"7","key":"2019041121342033200_B21","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"issue":"4","key":"2019041121342033200_B22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.leu.2402417","article-title":"The proteasome: a novel target for cancer chemotherapy","volume":"16","author":"Almond","year":"2002","journal-title":"Leukemia"},{"issue":"11","key":"2019041121342033200_B23","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"issue":"7","key":"2019041121342033200_B24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"2019041121342033200_B25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"40","key":"2019041121342033200_B26","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/onc.2009.214","article-title":"Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction","volume":"28","author":"Baritaki","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"2019041121342033200_B27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019041121342033200_B28","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.2174\/1381612811319220015","article-title":"Drug combinations with proteasome inhibitors in antitumor therapy","volume":"19","author":"Gatti","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2019041121342033200_B29","unstructured":"NCT00644696. Study of irinotecan and bortezomib in children with recurrent\/refractory neuroblastoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00644696?term=bortezomib&rank=3. Accessed 11 October 2016."},{"key":"2019041121342033200_B30","unstructured":"NCT02903069. Study of marizomib with temozolomide and radiotherapy in patients with newly diagnosed brain cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02903069?term=NPI-0052&rank=7. Accessed 2 May 2017."},{"issue":"12","key":"2019041121342033200_B31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1593\/neo.05520","article-title":"Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells","volume":"7","author":"Shirley","year":"2005","journal-title":"Neoplasia"},{"issue":"1","key":"2019041121342033200_B32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4161\/cc.4.1.1363","article-title":"Life and death in cancer: GADD45 alpha and gamma are critical regulators of NF-kappaB mediated escape from programmed cell death","volume":"4","author":"Zerbini","year":"2005","journal-title":"Cell Cycle"},{"issue":"10","key":"2019041121342033200_B33","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/ijc.27524","article-title":"NF-\u03baB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model","volume":"131","author":"Pacak","year":"2012","journal-title":"Int J Cancer"},{"issue":"7","key":"2019041121342033200_B34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/156800905774574075","article-title":"Anti-angiogenic and anti-tumor properties of proteasome inhibitors","volume":"5","author":"Daniel","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"2019041121342033200_B35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/bbrc.1998.8604","article-title":"The proteasome is involved in angiogenesis","volume":"246","author":"Oikawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019041121342033200_B36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000087894","article-title":"Anti-angiogenic effect of bortezomib in patients with multiple myeloma","volume":"114","author":"Politou","year":"2005","journal-title":"Acta Haematol"},{"issue":"18 Pt 1","key":"2019041121342033200_B37","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors","volume":"10","author":"Shah","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019041121342033200_B38","first-page":"135","article-title":"Bortezomib as a therapeutic candidate for neuroblastoma","volume":"7","author":"Armstrong","year":"2008","journal-title":"J Exp Ther Oncol"},{"issue":"2","key":"2019041121342033200_B39","first-page":"439","article-title":"Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo","volume":"28","author":"Michaelis","year":"2006","journal-title":"Int J Oncol"},{"issue":"4","key":"2019041121342033200_B40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/1078-0432.CCR-08-2477","article-title":"The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response","volume":"15","author":"Pagnan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019041121342033200_B41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.surg.2007.04.012","article-title":"Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma","volume":"142","author":"Hamner","year":"2007","journal-title":"Surgery"},{"key":"2019041121342033200_B42","unstructured":"NCT01132911\n          \n          . A Phase I study of vorinostat and bortezomib in children with refractory of recurrent solid tumors, including CNS tumors and lymphomas. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01132911?term=bortezomib+neuroblastoma&rank=4. Accessed 2 May 2017."},{"key":"2019041121342033200_B43","unstructured":"NCT02139397\n          . Study of DFMO in combination with bortezomib for relapsed or refractory neuroblastoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02139397?term=bortezomib+neuroblastoma&rank=2. Accessed 11 October 2016."},{"key":"2019041121342033200_B44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1755-8794-5-48","article-title":"Integrative analysis of neuroblastoma and pheochromocytoma genomics data","volume":"5","author":"Szab\u00f3","year":"2012","journal-title":"BMC Med Genomics"},{"key":"2019041121342033200_B45","unstructured":"NCT00833560. Clinical study on induction of remission using bortezomib (Vel), cyclophosphamide (C), and dexamethasone (D) in patients until 60 years of age with untreated multiple myeloma and planned for a high dose chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00833560?term=bortezomib+cyclophosphamide&recrs=de&phase=12&draw=2&rank=1. Accessed 31 July 2017."},{"key":"2019041121342033200_B46","unstructured":"NCT02467010. Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naive multiple myeloma patients: a prospective phase II study. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02467010?term=bortezomib+cyclophosphamide&recrs=de&phase=12&draw=2&rank=2. Accessed 31 July 2017."},{"key":"2019041121342033200_B47","unstructured":"NCT00722137\n          \n          . A randomized, open-label, multicentre phase 3 study of the combination of rituximab, cyclophosphamide, doxorubicin, VELCADE, and prednisone or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed mantle cell lymphoma who are not eligible for a bone marrow transplant. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00722137?term=NCT00722137&rank=1. Accessed 31 July 2017."},{"key":"2019041121342033200_B48","unstructured":"NCT00958256\n          . Phase II study of bortezomib in combination with cyclophosphamide and rituximab for relapsed\/refractory mantle cell lymphoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00958256?term=NCT00958256&rank=1. Accessed 31 July 2017."},{"issue":"11","key":"2019041121342033200_B49","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1096\/fj.12-210146","article-title":"Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function","volume":"26","author":"Yang","year":"2012","journal-title":"FASEB J"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/158\/10\/3097\/20425029\/en.2017-00592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T10:03:39Z","timestamp":1555063419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/158\/10\/3097\/4082468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,8,15]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2017-00592","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,1]]},"published":{"date-parts":[[2017,8,15]]}}}